US-based biotechnology company Massive Bio and molecular insights company Foundation Medicine have teamed up to enhance patient access to advanced clinical trials.
The collaboration aims to improve the low rate of patient enrollment in oncology clinical trials, where only about 8% of eligible cancer patients participate in clinical trials.
Under the partnership, Massive Bio will leverage its patient-matching technology and last-mile solutions and Foundation Medicine its expertise in next-generation sequencing (NGS) and its network of healthcare providers.
The partnership will enable integrated patient-matching solutions that support both Massive Bio’s and Foundation Medicine’s customers through shared data and AI analytics.
Massive Bio co-founder and chief medical officer Arturo Loaiza-Bonilla said: “The application of real-time AI and our comprehensive data significantly boosts the speed and accuracy of clinical trial matching.
“This capability allows us to provide individualised treatments more quickly and accurately, enhancing patient outcomes across the globe.
“Joining forces with Foundation Medicine is pivotal as it will allow us to develop solutions to the cancer clinical trial enrollment paradox.”
Massive Bio is building a large-scale oncology/haematology network with more than 132,000 patients, 5,000 physicians, 40 pharma and CRO customers and 50 partners.
Its real-time, AI-driven platform, dubbed Synergy-AI, can analyse medical records, including biomarker data from multiple sources, to match patients with over 16,000 clinical trials instantly.
Also, the biotechnology company’s predictive analytics maximise trial enrollment potential and significantly reduce screen failures.
Under the partnership, Massive Bio and Foundation Medicine would enhance clinical trial enrollment with their extensive networks and capabilities across the healthcare landscape.
The two companies will employ advanced AI techniques and an extensive digital health platform to optimise clinical trial processes and enhance precision oncology.
Foundation Medicine clinical and scientific operations senior vice president Heather Jorajuria said: “Beyond providing high-quality genomic profiling to support informed decision-making, Foundation Medicine is committed to empowering practitioners to act on those decisions by identifying personalised treatment options including clinical trials.
“Through this partnership with Massive Bio, we have the patient at the forefront, leveraging our combined assets and expertise to improve access to clinical trials for patients.”
